www.nature.com/scientificreports OPEN Application of fuorescein combined with methylene blue in sentinel lymph node biopsy of breast cancer Liang Li1, Ning Gao1*, Ai Qing Yang2, Wen Hao Xu1, Yu Ding1, Jun Chu1, Xiao Na Lin1 & Jia Qi Liu1 Sentinel lymph node biopsy (SLNB) for axillary lymph node staging in early breast cancer has been widely recognized. The combination of radio-colloids and dye method is the best method recognized. The reagents and equipment required in the process of the combined method are complex and expensive, so there are certain restrictions in the use of primary medical institutions. As a new tracer, fuorescent tracer technology has attracted much attention. We aimed to evaluate the feasibility and safety of fuorescein for SLNB in breast cancer. In this study, a total of 123 patients with breast cancer were divided into group A (n = 67) and group B (n = 56). The efcacy of Indocyanine green (ICG) combined with methylene blue (group A) and fuorescein combined with methylene blue (group B) in SLNB of breast cancer was compared, complications were observed at the same time. No local or systemic reactions were observed in the two groups. In group A, Sentinel lymph nodes of breast cancer were detected in 63 patients, with a detection rate of 94.0% (63/67), a false-negative rate of 7.5% (4/53). In group B, Sentinel lymph nodes of breast cancer were detected in 52 patients, with a detection rate of 92.9% (52/56), a false-negative rate of 7.5% (3/40). There was no signifcant diference in biopsy results between the two groups. This prospective clinical study suggests that SLNB using fuorescein and ultraviolet LED light is feasible in breast cancer patients. No adverse reactions were observed in this study, but larger studies are needed to properly assess the adverse reaction rate. Sentinel lymph node biopsy (SLNB) for axillary lymph node staging in early breast cancer has been widely rec- ognized. Blue dye, radio-colloids, or both can be used to identify the sentinel lymph node 1,2. Te biggest problem of SLNB using blue dye alone is that its detection rate is only 70–86%. Te combination of radio-colloids and the blue dye method can signifcantly improve the detection rate of SLNB, which is the best method recognized in the clinic3. However, Radio-colloids are expensive, complex, require the cooperation of the nuclear medicine department, which is difcult to carry out in primary hospitals. Also, It needs to be injected preoperatively, which can cause signifcant pain to patients and also cause concern for patients and physicians about radiation exposure. As a new tracer, fuorescent tracer technology has attracted much attention4. Indocyanine green (ICG) is the most commonly used fuorescent tracer 5. It refects fuorescence when excited by certain wavelengths of near-infrared light, and the signal is processed by a computer to transmit the image to a screen. Terefore, a fuorescent imaging system with a near-infrared camera is required to perform SLNB by looking at the monitor rather than the surgical feld. Fluorescein is a fuorescent tracer widely used in ophthalmology and optometry. It can be excited by ultra- violet or blue light through thin tissue to appear green and yellow light. SLNB use fuorescein requires an only blue or ultraviolet light torch, which reduces the cost of surgery and is easy to be applied in primary hospitals. Recent animal studies have shown that fuorescein can also be used to locate axillary lymph nodes in rabbits 6. In this study, the efcacy of ICG combined with methylene blue and fuorescein combined with methylene blue in SLNB of breast cancer was compared. 1Department of Breast Surgery, Zibo Central Hospital, Shandong First Medical University, Zibo, Shandong Province, China. 2Zibo Center for Disease Control and Prevention, Zibo, Shandong Province, China. *email: [email protected] Scientifc Reports | (2021) 11:12119 | https://doi.org/10.1038/s41598-021-91641-1 1 Vol.:(0123456789) www.nature.com/scientificreports/ Value Characteristic Group A (n = 67) Group B (n = 56) Age (years) 47 (26–73) 49 (30–72) Body mass index (kg/m2) 23.3 (18–36) 23.9 (17–37) Tumor size (cm) 1.8 (0.5–4.0) 1.6 (0.7–3.8) TNM staging Tumor pT1 46 (68.7%) 39 (69.6%) pT2 21 (31.3%) 17 (30.4%) Node pN0 13 (19.4%) 15 (26.8%) pN1 49 (73.1%) 34 (60.7%) pN2 5 (7.5%) 7 (12.5%) Table 1. Clinical characteristic of the patients enrolled in this study. TNM staging, Tumor, node and metastasis staging. Materials and methods Clinical data. From July 2019 to December 2020, 123 patients with feasible SLNB of breast cancer admitted to our hospital were studied. According to the order of admission, they were divided into group A (n = 67) and group B (n = 56). (Table 1) All of them provided written informed consent. Te protocol and consent procedures were approved by the Institutional Review Board of Zibo Central Hospital afliated with Shandong First Medi- cal University, and all experiments were performed following relevant guidelines and regulations. Te Chinese Clinical Trial Registry (available at http:// www. chictr. org. cn/) approved the clinical nature of this study (registra- tion number: ChiCTR2000036990). Methods. First, the fuorescent dye was injected. ICG solution was used in group A (25 mg ICG powder was diluted with 9 mL of water for injection, and then 0.1 mL of the diluted solution was extracted with a 1 mL syringe and continued to be diluted to 1 mL with 0.9% normal saline), and fuorescein solution was used in group B(1:5 fuorescein solution (10% fuorescein solution 1 mL and 0.9% normal saline 4 mL were mixed into the solution, with an average pH value of 8.97 (8.95–9.02)7). Te intradermal injection was made into the outer upper quadrant of the areola at 3–4 points, the total amount is about 0.1 to 0.3 ml. Group B patients were tested for fuorescein allergy (0.1 ml 10% fuorescein solution was diluted to 5 ml with 0.9% normal saline, injected intravenously, and observed for 10 min) no positive results were found8. Afer 3 min, a 1 ml syringe was used to select 1–3 points on the outside of the areola for intradermal injection of methylene blue, with a total amount of about 0.1–0.3 ml. 10 min later, the operating lights were turned of. Te images of group A were collected using the near-infrared camera system, and group B was marked with an ultraviolet (wavelength 395 nm) LED torch (LOFTEK, China) to mark the direction of lymph vessels and the location of their disappearance (Fig. 1). An incision was made approximately 1 cm from the distal end of lymph vessel disappearance. If there is no obvious lymph vessel, an incision is made at the inferior axillary fold. Group A was guided by an infrared probe and group B was guided by the ultraviolet LED torch to identify the fuorescent and methylene blue-stained lymph vessels, and then followed the lymph vessels to remove the sentinel lymph nodes (Fig. 2). All lymph nodes were examined by frozen pathology and conventional parafn pathology. For the sentinel lymph nodes with no metastatic cancer, only the lower axillary lymph nodes were dissected. Routine axillary lymph node dissection was performed in patients with sentinel lymph node metastasis. Main outcome measures. Te results of SLNB in groups A and B were compared, including detection rate, false-negative rate, number of sentinel lymph nodes. Evaluation of complications in fuorescein group. Anaphylaxis and systemic urticaria were observed within 20 min of the operation. Te skin necrosis at the injection site was observed within 1 week. Liver and kidney functions were measured 7 days afer the operation. Te color changes of skin and urine at the injection site were observed 2 days afer the operation. Statistical analysis. All statistics were analyzed using IBM SPSS 22.0 statistics sofware. (IBM Co., Armonk, NY, USA) Continuous variables are expressed as median or mean, and categorical variables as percentages. T-test was used for the comparison of measurement data and X2 test was used for the comparison of counting data. When the p-value was less than 0.05, the diference was considered statistically signifcant. Results Comparison of biopsy results between the two groups. A total of 123 eligible women with breast cancer were enrolled (Table 1). Te patients ranged in age from 26 to 73 years. Scientifc Reports | (2021) 11:12119 | https://doi.org/10.1038/s41598-021-91641-1 2 Vol:.(1234567890) www.nature.com/scientificreports/ Figure 1. Lymph vessel (arrow) shown by fuorescein during the operation. Figure 2. Lymph node (arrow) shown by fuorescein during the operation. Group A (n = 67) Group B (n = 56) P (ICG + MB vs ICG + MB (ICG MB) Flu + MB (Flu MB) Flu + MB) Detection Rate (%) 94.0 (63/67) 89.6 (60/67) 79.1 (53/67) 92.9 (52/56) 87.5 (49/56) 83.9 (47/56) 1.000 False-negative rate (%) 7.5 (4/53) – – 7.5 (3/40) – – 1.000 Number of SLNs 3.0 (1–6) 3.0 (1–5) 3.0 (1–6) 3.5 (1–6) 3.0 (1–6) 3.0 (1–5) 0.406 Table 2. Comparison of biopsy results between the two groups. ICG Indocyanine green, MB Methylene blue, Flu Fluorescein, SLNs sentinel lymph nodes. No local or systemic reactions were observed in 67 patients in group A. Sentinel lymph nodes of breast cancer were detected in 63 patients, with a detection rate of 94.0% (63/67), a false-negative rate of 7.5% (4/53).